Navigation Links
Bioniche Reports Fiscal 2007 Year-End Results
Date:9/26/2007

p>

$ $

-------------------------------------------------------------------------

ASSETS

Current

Cash and cash equivalents 1,523,597 4,093,293

Short-term investments 9,500,000 -

Accounts receivable 5,495,836 5,644,956

Inventories 5,480,167 6,171,453

Prepaid expenses and deposits 658,867 804,470

-------------------------------------------------------------------------

22,658,467 16,714,172

-------------------------------------------------------------------------

Long-term

Property, plant and equipment 9,557,359 10,138,797

Intangible assets 8,545,215 9,401,733

Goodwill 456,155 456,155

Deferred financing fees 209,578 1,258,236

Investment - 3,298,279

Other assets 100,000 100,000

-------------------------------------------------------------------------

41,526,774 41,367,372

-------------------------------------------------------------------------

-------------------------------------------------------------------------

LIABILITIES AND SHAREHOLDERS' EQUITY

Current

Revolving credit facility 895,619 3,162,097

Accounts payable and accrued liabilities 6,399,382 5,054,593

Income and other taxes payable 283,845 494,881

Deferred government incentives 541,282 3,433,00
'/>"/>

SOURCE Bioniche Life Sciences Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. TomoTherapy reports 86% revenue jump, $131M net loss in Q1
2. Sonic Foundry reports GAAP loss as Q2 revenues rise
3. Fiserv reports $113.5 million in Q1 profit
4. Third Wave reports net loss of $18.9M for 2006
5. Musicnotes reports 45 percent growth in 2006
6. Sonic Foundry reports net loss, higher revenue
7. Sonic Foundry reports first cash-positive quarter
8. Merge Healthcare reports $10.8M net loss in Q3
9. Third Wave reports $5.2M third quarter loss
10. Merge Healthcare appoints new CEO, reports $215 million Q2 loss
11. Merge files financial reports by market opening
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... NEW YORK , September 2, 2014 ... Market Study on Membrane Technology in Pharmaceutical, Biopharma and ... Witness Highest Growth by 2019" the global membrane technology market for ... 7,029.9 million in 2014 and is expected to grow ... to reach an estimated value of USD 10,886.0 million ...
(Date:9/2/2014)... Opertech Bio, Inc., a company that ... approach to sensory evaluation, today announced the issuance ... Patent and Trademark Office, encompassing high-throughput sensory discrimination ... taste evaluation technology called Microtiter Operant Gustometer or ... for rapid characterization of taste sensory properties,” said ...
(Date:9/2/2014)... 2014  Synthetic Biologics, Inc. (NYSE MKT: SYN), ... candidates targeting specific pathogens that cause serious infections ... final preclinical toxicology study of SYN-004. Per U.S. ... study was required to move the Company,s lead ... devastating effects of Clostridium difficile (C. difficile), ...
(Date:9/2/2014)... September 2, 2014 Culot brings ... and lab management services  BioData, producer of ... pleased to announce the appointment of Louis Culot ... served as VP Marketing and Business Development at BioDiscovery ... and clinical applications. Previously, Culot worked for ...
Breaking Biology Technology:Global Membrane Technology Market Will Reach $10,886.0 Million in 2019: Persistence Market Research 2Global Membrane Technology Market Will Reach $10,886.0 Million in 2019: Persistence Market Research 3Global Membrane Technology Market Will Reach $10,886.0 Million in 2019: Persistence Market Research 4Global Membrane Technology Market Will Reach $10,886.0 Million in 2019: Persistence Market Research 5Opertech Bio Receives U.S. Patent for High-Throughput Taste Evaluation Technology 2Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 2Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 3Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 4Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 5Louis Culot Appointed as BioData's CEO 2
... 29 Abt Associates has been,ranked 19th in the ... 50 U.S. Research firms. The listing is based on ... research revenue for,calendar 2007 was $55.1 million. Total company ... $225 million., Abt Associates market research activities are ...
... Purification Testing, Standards and Procedures, SHAANXI, China, ... (OTC Bulletin Board: HFGB), a leading,developer and producer ... the,production of pharmaceuticals, nutraceuticals and food production, today,released ... application for COS,approval for the delivery of Diosmin ...
... Volcano Corporation,(Nasdaq: VOLC ), a leading ... (FM) and Optical Coherence,Tomography (OCT) products designed to ... vascular disease, today announced that it will,report its ... six months of,fiscal 2008 on Tuesday, August 5., ...
Cached Biology Technology:Abt Associates Ranked One of Top 20 U.S. Market Research Firms 2Huifeng Bio-Pharmaceutical (HFGB) Provides Update on COS Application Status 2Huifeng Bio-Pharmaceutical (HFGB) Provides Update on COS Application Status 3Volcano Corporation Schedules Second Quarter Conference Call, Webcast 2
(Date:9/2/2014)... the battle between our immune systems and cholera bacteria, ... known as phages. In a new study, researchers from ... National Public Health Laboratory, and elsewhere, report that phages ... in order to survive. Importantly, the study published ... escape from phage predation occurs during human infection. , ...
(Date:9/2/2014)... Kean stops by Reactions this week to debunk the ... despite what "Shark Week" may lead you to believe, ... http://youtu.be/KhFygIoW_MA . , Kean,s book, "The Disappearing Spoon: And ... of the World from the Periodic Table of the ... video series produced for the newly launched American Association ...
(Date:9/2/2014)... touch a hot oven, you rapidly pull your hand ... in sensing and responding to such painful stimuli, they ... researchers have made a surprising discovery about the role ... and have built a structural model of the molecule. ... , may help direct new strategies to treat pain ...
Breaking Biology News(10 mins):War between bacteria and phages benefits humans 2War between bacteria and phages benefits humans 3Surprising new role for calcium in sensing pain 2Surprising new role for calcium in sensing pain 3
... University of the Negev researcher Dr. Taleb Mokari, a ... and Technology, has been awarded a prestigious Krill Prize ... the Prize for his work on developing novel nanostructures ... a senior lecturer in BGU,s Department of Chemistry. His ...
... of time families spend eating meals together has been ... teens, with families who eat together regularly reporting declines ... their children. Now, a new study that looks at ... family interactions during mealtime affected the children,s health. ...
... percent of dairy herds and causes an estimated annual ... A contagious, chronic and usually fatal bacterial infection of ... milk production, causes weight loss in cows, and contributes ... Institute for Mathematical and Biological Synthesis (NIMBioS) is now ...
Cached Biology News:Family mealtimes play a role in health of children with asthma 2Wasting disease in cattle focus of workshop 2
EGTA, 10 g. Ethylene glycol-O,O-bis-[2-amino-ethyl]-N,N,N,N,-tetraacetic acid.Assay: > 99.0%. Category: Nucleotides & Enzymes & Biochemicals, Ultrapure Biochemicals ....
...
RABBIT ANTI D-TYROSINE CONJUGATE...
... PCR Spots, Oligo Spots and complementary RNA ... microarray experiments. Use for glass array printing ... for reverse transcription, cDNA labeling, hybridization stringency ... Control PCR Spots and Oligo Spots, ...
Biology Products: